Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.
Ageing
Ganglioside
Glucocerebrosidase
Glycosphingolipid
Lysosome
Neurodegeneration
Parkinson’s disease
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
08 11 2019
08 11 2019
Historique:
received:
03
05
2019
accepted:
20
09
2019
entrez:
10
11
2019
pubmed:
11
11
2019
medline:
24
6
2020
Statut:
epublish
Résumé
Haploinsufficiency in the Gaucher disease GBA gene, which encodes the lysosomal glucocerebrosidase GBA, and ageing represent major risk factors for developing Parkinson's disease (PD). Recently, more than fifty other lysosomal storage disorder gene variants have been identified in PD, implicating lysosomal dysfunction more broadly as a key risk factor for PD. Despite the evidence of multiple lysosomal genetic risks, it remains unclear how sphingolipid hydrolase activities, other than GBA, are altered with ageing or in PD. Moreover, it is not fully known if levels of glycosphingolipid substrates for these enzymes change in vulnerable brain regions of PD. Finally, little is known about the levels of complex gangliosides in substantia nigra which may play a significant role in ageing and PD. To study sphingolipid hydrolase activities and glycosphingolipid expression in ageing and in PD, two independent cohorts of human substantia nigra tissues were obtained. Fluorescent 4-methylumbelliferone assays were used to determine multiple enzyme activities. The lysosomal GBA and non-lysosomal GBA2 activities were distinguished using the inhibitor NB-DGJ. Sensitive and quantitative normal-phase HPLC was performed to study glycosphingolipid levels. In addition, glycosphingolipid levels in cerebrospinal fluid and serum were analysed as possible biomarkers for PD. The present study demonstrates, in two independent cohorts of human post-mortem substantia nigra, that sporadic PD is associated with deficiencies in multiple lysosomal hydrolases (e.g. α-galactosidase and β-hexosaminidase), in addition to reduced GBA and GBA2 activities and concomitant glycosphingolipid substrate accumulation. Furthermore, the data show significant reductions in levels of complex gangliosides (e.g. GM1a) in substantia nigra, CSF and serum in ageing, PD, and REM sleep behaviour disorder, which is a strong predictor of PD. These findings conclusively demonstrate reductions in GBA activity in the parkinsonian midbrain, and for the first time, reductions in the activity of several other sphingolipid hydrolases. Furthermore, significant reductions were seen in complex gangliosides in PD and ageing. The diminished activities of these lysosomal hydrolases, the glycosphingolipid substrate accumulation, and the reduced levels of complex gangliosides are likely major contributors to the primary development of the pathology seen in PD and related disorders with age.
Sections du résumé
BACKGROUND
Haploinsufficiency in the Gaucher disease GBA gene, which encodes the lysosomal glucocerebrosidase GBA, and ageing represent major risk factors for developing Parkinson's disease (PD). Recently, more than fifty other lysosomal storage disorder gene variants have been identified in PD, implicating lysosomal dysfunction more broadly as a key risk factor for PD. Despite the evidence of multiple lysosomal genetic risks, it remains unclear how sphingolipid hydrolase activities, other than GBA, are altered with ageing or in PD. Moreover, it is not fully known if levels of glycosphingolipid substrates for these enzymes change in vulnerable brain regions of PD. Finally, little is known about the levels of complex gangliosides in substantia nigra which may play a significant role in ageing and PD.
METHODS
To study sphingolipid hydrolase activities and glycosphingolipid expression in ageing and in PD, two independent cohorts of human substantia nigra tissues were obtained. Fluorescent 4-methylumbelliferone assays were used to determine multiple enzyme activities. The lysosomal GBA and non-lysosomal GBA2 activities were distinguished using the inhibitor NB-DGJ. Sensitive and quantitative normal-phase HPLC was performed to study glycosphingolipid levels. In addition, glycosphingolipid levels in cerebrospinal fluid and serum were analysed as possible biomarkers for PD.
RESULTS
The present study demonstrates, in two independent cohorts of human post-mortem substantia nigra, that sporadic PD is associated with deficiencies in multiple lysosomal hydrolases (e.g. α-galactosidase and β-hexosaminidase), in addition to reduced GBA and GBA2 activities and concomitant glycosphingolipid substrate accumulation. Furthermore, the data show significant reductions in levels of complex gangliosides (e.g. GM1a) in substantia nigra, CSF and serum in ageing, PD, and REM sleep behaviour disorder, which is a strong predictor of PD.
CONCLUSIONS
These findings conclusively demonstrate reductions in GBA activity in the parkinsonian midbrain, and for the first time, reductions in the activity of several other sphingolipid hydrolases. Furthermore, significant reductions were seen in complex gangliosides in PD and ageing. The diminished activities of these lysosomal hydrolases, the glycosphingolipid substrate accumulation, and the reduced levels of complex gangliosides are likely major contributors to the primary development of the pathology seen in PD and related disorders with age.
Identifiants
pubmed: 31703585
doi: 10.1186/s13024-019-0339-z
pii: 10.1186/s13024-019-0339-z
pmc: PMC6842240
doi:
Substances chimiques
alpha-Synuclein
0
Hydrolases
EC 3.-
Glucosylceramidase
EC 3.2.1.45
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
40Subventions
Organisme : Wellcome Trust
ID : 202834/Z/16/Z
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R01 AG060195
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Neurology. 1998 Jun;50(6):1630-6
pubmed: 9633704
Int J Dev Biol. 1991 Sep;35(3):289-95
pubmed: 1814411
Neuropharmacology. 1986 Sep;25(9):1075-7
pubmed: 3490632
Mol Genet Metab. 2007 Dec;92(4):336-45
pubmed: 17881272
Neuron. 2018 Jan 3;97(1):92-107.e10
pubmed: 29290548
J Biol Chem. 2013 Feb 1;288(5):3381-93
pubmed: 23250757
Biochemistry. 2007 Feb 20;46(7):1868-77
pubmed: 17253773
Am J Hum Genet. 2013 Feb 7;92(2):238-44
pubmed: 23332916
J Inherit Metab Dis. 2006 Dec;29(6):707-15
pubmed: 17080304
J Biol Chem. 2007 Nov 9;282(45):32655-64
pubmed: 17848577
Neurochem Res. 2012 Jun;37(6):1344-54
pubmed: 22350518
Trends Biochem Sci. 2015 Jul;40(7):407-18
pubmed: 26024958
J Clin Invest. 2006 Nov;116(11):2985-94
pubmed: 17080196
PLoS One. 2015 Aug 14;10(8):e0135889
pubmed: 26275242
Cell. 2011 Jul 8;146(1):37-52
pubmed: 21700325
Mov Disord. 2005 Oct;20(10):1366-9
pubmed: 15986423
Exp Neurol. 1991 Sep;113(3):301-5
pubmed: 1915720
N Engl J Med. 2009 Oct 22;361(17):1651-61
pubmed: 19846850
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):127-43
pubmed: 25987168
Front Neurosci. 2018 Feb 05;12:45
pubmed: 29459819
PLoS One. 2013 Sep 18;8(9):e73094
pubmed: 24058461
PLoS One. 2017 Jan 4;12(1):e0169309
pubmed: 28052128
Anal Biochem. 2004 Aug 15;331(2):275-82
pubmed: 15265733
Mov Disord. 2015 Jul;30(8):1085-9
pubmed: 26096906
Lancet Neurol. 2013 May;12(5):443-53
pubmed: 23562390
Mol Genet Metab. 2003 Jun;79(2):104-9
pubmed: 12809640
PLoS One. 2011;6(6):e21758
pubmed: 21738789
Neurology. 2013 Apr 23;80(17):1606-10
pubmed: 23535491
J Neurosci Res. 2012 Oct;90(10):1997-2008
pubmed: 22714832
J Oleo Sci. 2011;60(10):537-44
pubmed: 21937853
Ann Neurol. 1992 Mar;31(3):328-32
pubmed: 1353343
Brain Res. 1983 Feb 14;261(1):163-6
pubmed: 6132660
Mov Disord. 2007 Jul 30;22(10):1481-4
pubmed: 17546678
Nat Commun. 2014 Jun 06;5:4028
pubmed: 24905578
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
J Neurochem. 1976 Oct;27(4):943-8
pubmed: 184255
Nat Genet. 1995 Oct;11(2):170-6
pubmed: 7550345
PLoS One. 2014 Feb 26;9(2):e89741
pubmed: 24587002
J Neurol Sci. 2008 Aug 15;271(1-2):168-73
pubmed: 18495164
J Biol Chem. 2007 Jan 12;282(2):1305-12
pubmed: 17105727
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Acta Neuropathol Commun. 2014 Feb 14;2:20
pubmed: 24529306
J Neurosci. 2017 Oct 4;37(40):9617-9631
pubmed: 28847804
Neurol Sci. 2002 Jun;23(2):49-53
pubmed: 12235491
Trends Mol Med. 2011 Sep;17(9):485-93
pubmed: 21723784
Exp Neurol. 1989 Aug;105(2):177-83
pubmed: 2568945
Neurotoxicology. 2009 Nov;30(6):1127-32
pubmed: 19576930
Science. 1992 May 8;256(5058):843-6
pubmed: 1350379
Brain. 2013 Dec;136(Pt 12):3618-24
pubmed: 24103911
Mov Disord. 2011 Aug 1;26(9):1593-604
pubmed: 21618611
Gerontology. 1983;29(3):161-8
pubmed: 6852543
FASEB J. 2017 Aug;31(8):3467-3483
pubmed: 28442549
Neuroreport. 2003 Mar 24;14(4):551-4
pubmed: 12657883
J Mol Neurosci. 2015 Jul;56(3):617-22
pubmed: 25929833
J Biol Chem. 2013 Sep 6;288(36):26052-66
pubmed: 23880767
Mov Disord. 2004 Nov;19(11):1334-41
pubmed: 15389993
Nature. 2014 Jun 5;510(7503):68-75
pubmed: 24899306
QJM. 1996 Sep;89(9):691-4
pubmed: 8917744
Mov Disord. 2017 Oct;32(10):1423-1431
pubmed: 28843015
J Biol Chem. 2011 Aug 12;286(32):28080-8
pubmed: 21653695
Neurobiol Dis. 2018 Feb;110:68-81
pubmed: 29196214
J Biol Chem. 2017 Apr 14;292(15):6177-6189
pubmed: 28258214
Neurology. 2015 Apr 7;84(14):1454-64
pubmed: 25762709
Clin Chim Acta. 1981 Sep;115(3):369-75
pubmed: 6794954
Neurobiol Aging. 2018 Jul;67:189-200
pubmed: 29735433
Acta Neuropathol. 2007 Nov;114(5):481-9
pubmed: 17653558
Ann Clin Transl Neurol. 2015 Apr;2(4):433-8
pubmed: 25909088
Anal Chem. 2016 Feb 2;88(3):1856-63
pubmed: 26735924
Brain. 2017 Dec 1;140(12):3191-3203
pubmed: 29140481
Neurology. 2015 Mar 17;84(11):1104-13
pubmed: 25681454
Biochim Biophys Acta. 1993 Mar 24;1181(1):55-62
pubmed: 8457606
Genes Brain Behav. 2017 Jun;16(5):522-536
pubmed: 28239983
Ann N Y Acad Sci. 1998 Jun 19;845:363-73
pubmed: 9668369
Neurochem Res. 2011 Sep;36(9):1706-14
pubmed: 21399908
Sci Rep. 2018 Oct 12;8(1):15207
pubmed: 30315256
Neurosci Lett. 2014 Nov 7;583:188-93
pubmed: 25265039
Trends Biochem Sci. 2015 Jul;40(7):397-406
pubmed: 25941169
J Lipid Res. 2009 Apr;50 Suppl:S440-5
pubmed: 18845618
ASN Neuro. 2018 Jan-Dec;10:1759091418781889
pubmed: 29932343
Exp Neurol. 2015 Jan;263:177-89
pubmed: 25448159
J Neurol Sci. 2010 May 15;292(1-2):45-51
pubmed: 20206941
Orphanet J Rare Dis. 2013 Sep 26;8:151
pubmed: 24070122
Lancet Neurol. 2012 Nov;11(11):986-98
pubmed: 23079555
Brain. 2014 Mar;137(Pt 3):834-48
pubmed: 24477431
Am J Hum Genet. 2013 Feb 7;92(2):245-51
pubmed: 23332917
PLoS One. 2017 Feb 17;12(2):e0172348
pubmed: 28212433
Parkinsonism Relat Disord. 2017 Nov;44:58-65
pubmed: 28890071
J Mol Biol. 2011 May 13;408(4):654-69
pubmed: 21396938
Neurobiol Dis. 2018 Apr;112:85-90
pubmed: 29369793
J Neurol Sci. 2013 Dec 15;335(1-2):219-20
pubmed: 24035292
Ann Neurol. 2012 Sep;72(3):455-63
pubmed: 23034917
Mol Genet Metab. 2012 Apr;105(4):621-8
pubmed: 22366055
PLoS One. 2018 Jun 14;13(6):e0199189
pubmed: 29902255
Zebrafish. 2016 Jun;13(3):177-87
pubmed: 26909767
Mol Genet Metab Rep. 2017 Nov 09;14:27-30
pubmed: 29159076
Skelet Muscle. 2012 Nov 01;2(1):23
pubmed: 23114189
FEBS Lett. 2016 Mar;590(6):716-25
pubmed: 26898341
Trends Neurosci. 2017 Jan;40(1):4-14
pubmed: 27894611
J Neurochem. 1994 Nov;63(5):1802-11
pubmed: 7931336
Neurochem Int. 2018 Oct;119:97-106
pubmed: 29305919
Mov Disord. 2006 Jan;21(1):103-7
pubmed: 16149089
Nat Rev Dis Primers. 2018 Oct 1;4(1):27
pubmed: 30275469
PLoS One. 2018 Feb 26;13(2):e0193438
pubmed: 29481565